ALBO Albireo Pharma Inc

Price (delayed)

$18.94

Market cap

$370.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.7

Enterprise value

$164.2M

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and ...

Highlights
Albireo Pharma's EPS has surged by 75% YoY and by 4% QoQ
The net income has surged by 73% year-on-year and by 3.8% since the previous quarter
The quick ratio is down by 29% year-on-year but it is up by 25% since the previous quarter
The equity has declined by 16% since the previous quarter
The gross margin is down by 3.5% year-on-year

Key stats

What are the main financial stats of ALBO
Market
Shares outstanding
19.58M
Market cap
$370.78M
Enterprise value
$164.2M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.47
Price to sales (P/S)
8.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.61
Earnings
Revenue
$45.45M
EBIT
-$19.88M
EBITDA
-$19.53M
Free cash flow
-$108.67M
Per share
EPS
-$1.7
Free cash flow per share
-$5.61
Book value per share
$7.65
Revenue per share
$2.34
TBVPS
$12.59
Balance sheet
Total assets
$261.26M
Total liabilities
$113.08M
Debt
$10.08M
Equity
$148.19M
Working capital
$197.22M
Liquidity
Debt to equity
0.07
Current ratio
7.26
Quick ratio
6.92
Net debt/EBITDA
10.58
Margins
EBITDA margin
-43%
Gross margin
96.5%
Net margin
-72%
Operating margin
-271.2%
Efficiency
Return on assets
-12.1%
Return on equity
-21.2%
Return on invested capital
N/A
Return on capital employed
-8.7%
Return on sales
-43.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALBO stock price

How has the Albireo Pharma stock price performed over time
Intraday
2.16%
1 week
-3.56%
1 month
-8.5%
1 year
-47.05%
YTD
-18.68%
QTD
-36.51%

Financial performance

How have Albireo Pharma's revenue and profit performed over time
Revenue
$45.45M
Gross profit
$43.86M
Operating income
-$123.27M
Net income
-$32.73M
Gross margin
96.5%
Net margin
-72%
The net margin has soared by 95% year-on-year and by 14% since the previous quarter
ALBO's operating margin has soared by 78% year-on-year and by 11% since the previous quarter
The net income has surged by 73% year-on-year and by 3.8% since the previous quarter
The company's operating income fell by 16% YoY

Growth

What is Albireo Pharma's growth rate over time

Valuation

What is Albireo Pharma stock price valuation
P/E
N/A
P/B
2.47
P/S
8.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.61
Albireo Pharma's EPS has surged by 75% YoY and by 4% QoQ
ALBO's price to book (P/B) is 38% lower than its last 4 quarters average of 3.9 and 24% lower than its 5-year quarterly average of 3.2
The equity has declined by 16% since the previous quarter
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 10061.8 and 79% lower than the last 4 quarters average of 38.2
The revenue has grown by 12% from the previous quarter

Efficiency

How efficient is Albireo Pharma business performance
Albireo Pharma's return on sales has surged by 96% YoY and by 12% QoQ
Albireo Pharma's return on assets has surged by 74% YoY and by 4.7% QoQ
Albireo Pharma's return on equity has surged by 72% YoY and by 3.6% QoQ

Dividends

What is ALBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALBO.

Financial health

How did Albireo Pharma financials performed over time
The total assets is 131% more than the total liabilities
Albireo Pharma's current ratio has decreased by 29% YoY but it has increased by 22% from the previous quarter
The quick ratio is down by 29% year-on-year but it is up by 25% since the previous quarter
The debt is 93% smaller than the equity
The debt to equity has grown by 17% since the previous quarter
The equity has declined by 16% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.